BENZALKONIUM CHLORIDE 0.13% and THERAPY NON RESPONDER

Overview

THERAPY NON RESPONDER is the #5 most commonly reported adverse reaction for BENZALKONIUM CHLORIDE 0.13%, manufactured by Meijer, Inc.. There are 110 FDA adverse event reports linking BENZALKONIUM CHLORIDE 0.13% to THERAPY NON RESPONDER. This represents approximately 3.3% of all 3,369 adverse event reports for this drug.

Patients taking BENZALKONIUM CHLORIDE 0.13% who experience therapy non responder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

THERAPY NON RESPONDER is moderately reported among BENZALKONIUM CHLORIDE 0.13% users, representing a notable but not dominant share of adverse events.

Other Side Effects of BENZALKONIUM CHLORIDE 0.13%

In addition to therapy non responder, the following adverse reactions have been reported for BENZALKONIUM CHLORIDE 0.13%:

• DRUG INEFFECTIVE — 124 reports
• DRUG HYPERSENSITIVITY — 116 reports
• CONDITION AGGRAVATED — 112 reports
• ARTHRALGIA — 110 reports
• MUSCULOSKELETAL STIFFNESS — 108 reports
• PAIN IN EXTREMITY — 108 reports
• INFECTION — 107 reports
• HEPATOTOXICITY — 105 reports
• JOINT SWELLING — 105 reports
• MUSCULOSKELETAL PAIN — 105 reports

Other Drugs Associated with THERAPY NON RESPONDER

The following drugs have also been linked to therapy non responder in FDA adverse event reports:

Does BENZALKONIUM CHLORIDE 0.13% cause THERAPY NON RESPONDER?

THERAPY NON RESPONDER has been reported as an adverse event in 110 FDA reports for BENZALKONIUM CHLORIDE 0.13%. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is THERAPY NON RESPONDER with BENZALKONIUM CHLORIDE 0.13%?

THERAPY NON RESPONDER accounts for approximately 3.3% of all adverse event reports for BENZALKONIUM CHLORIDE 0.13%, making it a notable side effect.

What should I do if I experience THERAPY NON RESPONDER while taking BENZALKONIUM CHLORIDE 0.13%?

If you experience therapy non responder while taking BENZALKONIUM CHLORIDE 0.13%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages